trial

A Bioequivalence Study of PP3M in Patients With Schizophrenia

NCTId NCT07493551
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 260 (estimated)
Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Primary completion 2026-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
260 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2024-10-09
Primary completion
2026-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Lead Sponsor

Investigators

1
Gang Wang, M.D.Principal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
260
Phase
NA
Primary Completion Date
2026-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gang Wang, M.D.
person